VIRP Virbac SA
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric pheromone gel diffuser to soothe and reduce stress-related behaviors in dogs; Suigen Entero 3 is an inactivated vaccine aimed at preventing neonatal diarrhea in piglets caused by colibacillosis, clostridium, and rotavirus; Ursolyx soft chews formulated with ursolic acid that support muscle strength and mobility in dogs and cats; Zenifel a fogger and spray designed to reduce behaviors due to stress or undesirable behaviors in cats; Suigen PCV2 is a vaccine for porcine circovirus type 2; and Suigen Donoban is a multivalent vaccine used for the prevention of respiratory diseases in swine. It also provides a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, immunology, nutrition, petfood, and pharmaceutical products. In addition, the company serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Virbac (EPA: VIRP)
›
Virbac (EPA: VIRP) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 6,442 employees.
The shares were at 344.00 EUR on 19 November 2026, down 3.5% over 52 weeks. Its 52-week range is 297.00 EUR to 389.50 EUR: the price is 11.7% below the high and 15.8% above the low.
At a market capitalisation of 2.88B EUR, it trades at 18.4 times trailing earnings and 14.7 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, a discount of 30% for VIRP. It pays a dividend yielding 0.41% (it pays out 8% of its earnings), against a median of 2.43% among the dividend payers in that peer group.
Virbac reports return on equity of 13.4%, an operating margin of 15.8% and revenue up 4.0% year over year.
Its debt exceeds its cash by 188.93M EUR, a debt-to-equity ratio of 0.26. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 7 analysts cover the stock; their mean price target of 412.29 EUR is 19.9% above the current price. The next earnings report is expected on 19 March 2027.